SIL index including stage, soluble interleukin-2 receptor, and LDH is as a useful prognostic predictor in DLBCL
Cancer Science, 05/21/2012
Clinical Article
Tomita N et al. – The soluble interleukin index is a simple and objective prognostic index for diffuse large B–cell lymphoma (DLBCL) patients to identify candidates for experimental therapy other than Rituximab (R) plus CHOP chemotherapy (R–CHOP).



